CAR T-Cell Therapies Moving to Outpatient Setting

The high durable response rates seen with CAR T-cell therapies have helped fill a high unmet need for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), with questions remaining on the optimal way to use these agents following the FDA approval of two therapies in the past year. Now, with added experience in the clinic, researchers are looking to move these therapies to the outpatient treatment setting, as opposed to hospital administration. This move is meant to address reimbursement concerns, as hospitalization costs can surpass treatment costs in some scenarios. “We have been trying to go in the outpatient setting, trying to use Kymriah in this context, because there seems to be less [cytokine release syndrome] in the first 72 hours with this agent,” Andre Goy, M.D., chair and director of John Theurer Cancer Center at Hackensack University Medical Center, said during a panel discussion at the 36th Annual CFS®. “We’ve done half of patients in this setting, and this seems good for this transition phase.” (This story was also covered by Targeted Oncology.)